Yaxiong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaxiong Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bo Peng Deng
Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, China
25 shared publications - Feng Hao
KYinno biotechnology Co., Ltd, Beijing, China
25 shared publications - Guoqian Wang
KYinno biotechnology Co., Ltd, Beijing, China
25 shared publications - Jing Li
Sun Yat-sen University Cancer Center
25 shared publications - Jun Liao
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
25 shared publications - Lanlan Pang
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
25 shared publications
Latest Publications
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 1. Study design.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 1. Study design.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 4. Drug sensitivity of different EGFR-TKIs in Ba/F3 cells expressing indicated EGFR p.G719S or EGFR p.E709K/G719S. (Data obtained from a public dataset of one published article, Reference: Nature. 2021 Sep; 597(7878):732-737.)
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 4. Drug sensitivity of different EGFR-TKIs in Ba/F3 cells expressing indicated EGFR p.G719S or EGFR p.E709K/G719S. (Data obtained from a public dataset of one published article, Reference: Nature. 2021 Sep; 597(7878):732-737.)
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 1. Study design.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 1. Study design.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 5. Baseline characteristics of TKI-naive EGFR p.G719X mutant patients diagnosed with NSCLC who received Afatinib or the third-generation EGFR-TKIs(N=68)
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 5. Baseline characteristics of TKI-naive EGFR p.G719X mutant patients diagnosed with NSCLC who received Afatinib or the third-generation EGFR-TKIs(N=68)
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 5. Baseline characteristics of TKI-naive EGFR p.G719X mutant patients diagnosed with NSCLC who received Afatinib or the third-generation EGFR-TKIs(N=68)
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 5. Baseline characteristics of TKI-naive EGFR p.G719X mutant patients diagnosed with NSCLC who received Afatinib or the third-generation EGFR-TKIs(N=68)
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 4. List of genes included in the SYSUCC Personalized Diagnostics Panel (Tumor tissue and blood sample control)
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 4. List of genes included in the SYSUCC Personalized Diagnostics Panel (Tumor tissue and blood sample control)
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 5. Structural modeling of EGFR p.G719A/E709K in a complex with afatinib.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 5. Structural modeling of EGFR p.G719A/E709K in a complex with afatinib.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 2. Baseline characteristics of treatment-naive patients diagnosed with NSCLC who harbored EGFR G719X mutation in SYSUCC cohort (n=48)
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 2. Baseline characteristics of treatment-naive patients diagnosed with NSCLC who harbored EGFR G719X mutation in SYSUCC cohort (n=48)
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 2. Impact of EGFR p.E709X mutation in patients harboring EGFR p.G719X mutant patients and genomic features of EGFR p.G719X mutant patients with NSCLC in the validation cohort.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 2. Impact of EGFR p.E709X mutation in patients harboring EGFR p.G719X mutant patients and genomic features of EGFR p.G719X mutant patients with NSCLC in the validation cohort.